Medigus:
Polyrizon Innovative Technology Demonstrated it may Prevent
Allergic Reaction Caused by Common Allergens
Polyrizon tested its Capture and
Contain (C&C™) proprietary hydrogel technology against house
dust mite allergen and Timothy grass pollen allergen in cell
culture assays
Tel Aviv, Israel - November 1,
2021 -- InvestorsHub NewsWire -- Medigus
Ltd. (Nasdaq:
MDGS), a technology company engaged in advanced medical
solutions, innovative internet technologies and electric vehicle
and charging solutions, today announced that Polyrizon Ltd.
(36.8%), informed Medigus that its pre-clinical data demonstrated a
potential to prevent allergic reaction induced by house dust mites
(HDM) and Timothy grass pollen allergens and may also prevent
respiratory tract allergy reactions caused by other
allergens.
Data from Polyrizon's cell-culture study, demonstrates that
its Capture and Contain (C&C™) innovative product, PL-14, has
the potential to reduce the inflammatory response while challenging
the host cells with group 1 allergens from Dermatophagoides
pteronyssinus (Der p1) and pollen major allergen (PhlP1) from
Timothy grass, which is a common perennial grass native to most of
Europe. House dust mites are microscopic, insect-like pests that
generate some of the most common indoor substances—or
allergens—that can trigger allergic reactions such as rhinitis,
asthma and atopic dermatitis, expressed with running nose, itchy
eyes, and skin itching in many people.
Grass pollen allergy is one of the most common allergies
worldwide and can trigger of allergic rhinitis (hay fever) and
asthma symptoms. Pollen seasons can last for several months and
exposure is difficult to avoid.
Polyrizon tested a few prototypes of its C&C platform as
a shield against Der p1 and PhlP1 allergens. In these studies, the
lead product candidate, PL14, prevents the interaction of the
allergen with the host cell, as expressed with reduced secretion of
the chemokine cytokine IL-8, an important inducer of allergic
reactions.
Polyrizon's lead product candidate, PL-14, has been designed
to protect the nasal cavity and the respiratory tract creating an
innate immune response by creating a physical barrier. This barrier
may prevent allergens from reaching the upper respiratory
epithelial cells and may decrease the inflammatory response that
leads to allergic reactions.
Recent pre-clinical studies by Polyrizon demonstrated the
impact of the C&C product line that was capable to provide a
barrier against allergens and a variety of different respiratory
viruses such as cold, flu and COVID-19.
The first efficacy results are expected within the next 12
months.
About Medigus
Based in Israel, Medigus Ltd. (Nasdaq: MDGS) is a technology
company focused on innovative growth partnerships, mainly in
advanced medical solutions, digital commerce and electric vehicle
markets. Medigus' affiliations in the medical solutions arena
include ownership in ScoutCam Inc. and Polyzion Ltd. The Company's
affiliates in digital commerce include Gix Internet Ltd., Jeff's
Brands Ltd. and Eventer Technologies Ltd. In the electric vehicle
market, Charging Robotics Ltd. and Revoltz Ltd. are also part of
the Company's portfolio of technology solution providers. To learn
more about Medigus' advanced technologies, please
visit http://www.medigus.com/.
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal
securities laws. Words such as "expects," "anticipates," "intends,"
"plans," "believes," "seeks," "estimates" and similar expressions
or variations of such words are intended to identify
forward-looking statements. For example, Medigus uses
forward-looking statements in this press release when it describes
the medical potential of the PL-14. Because such statements deal
with future events and are based on Medigus' current expectations,
they are subject to various risks and uncertainties, and actual
results, performance or achievements of Medigus could differ
materially from those described in or implied by the statements in
this press release.
The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties,
including those discussed in any filings with the Securities and
Exchange Commission ("SEC"). Except as otherwise required by law,
Medigus undertakes no obligation to publicly release any revisions
to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. References and links to websites have been
provided as a convenience, and the information contained on such
websites is not incorporated by reference into this press release.
Medigus is not responsible for the contents of third-party
websites.
Company Contact:
Tali Dinar
Chief Financial Officer
+972-8-6466-880
ir@medigus.com
Investor
Relations Contact:
Miri
Segal
CEO
MS-IR
LLC
+1-917-607-8654
msegal@ms-ir.com